{"title":"甲状腺结节的细胞学评估--2023 年贝塞斯达报告系统的更新、诊断挑战和陷阱","authors":"Xiaobing Jin, Xin Jing","doi":"10.1016/j.hpr.2024.300743","DOIUrl":null,"url":null,"abstract":"<div><p>This review summarizes changes and updates in the most recently published 2023 Bethesda System for Thyroid Cytopathology (TBSRTC). Further, the review focuses on challenges and pitfalls encountered in cytologic assessment of thyroid fine needle aspiration (FNA) specimens, with an emphasis on atypia of undetermined significance (TBSRTC category III) and the impact on risk of malignancy (ROM) among TBSRTC diagnostic categories following implementation of the terminology noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP). The role of molecular testing as an adjunct to FNA cytology will be discussed.</p></div>","PeriodicalId":100612,"journal":{"name":"Human Pathology Reports","volume":"36 ","pages":"Article 300743"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772736X2400015X/pdfft?md5=48d25cbcc58619bb1c7163158cb50e03&pid=1-s2.0-S2772736X2400015X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Cytologic assessment of thyroid nodules – Updates in 2023 Bethesda reporting system, diagnostic challenges and pitfalls\",\"authors\":\"Xiaobing Jin, Xin Jing\",\"doi\":\"10.1016/j.hpr.2024.300743\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This review summarizes changes and updates in the most recently published 2023 Bethesda System for Thyroid Cytopathology (TBSRTC). Further, the review focuses on challenges and pitfalls encountered in cytologic assessment of thyroid fine needle aspiration (FNA) specimens, with an emphasis on atypia of undetermined significance (TBSRTC category III) and the impact on risk of malignancy (ROM) among TBSRTC diagnostic categories following implementation of the terminology noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP). The role of molecular testing as an adjunct to FNA cytology will be discussed.</p></div>\",\"PeriodicalId\":100612,\"journal\":{\"name\":\"Human Pathology Reports\",\"volume\":\"36 \",\"pages\":\"Article 300743\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2772736X2400015X/pdfft?md5=48d25cbcc58619bb1c7163158cb50e03&pid=1-s2.0-S2772736X2400015X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Pathology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772736X2400015X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Pathology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772736X2400015X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本综述总结了最新出版的《2023 年甲状腺细胞病理学贝塞斯达系统》（TBSRTC）的变化和更新。此外，本综述还将重点关注甲状腺细针穿刺（FNA）标本细胞学评估中遇到的挑战和陷阱，重点是意义未定的不典型性（TBSRTC III 类），以及在采用具有乳头状核特征的非侵袭性滤泡性肿瘤（NIFTP）这一术语后对 TBSRTC 诊断类别中恶性肿瘤风险（ROM）的影响。还将讨论分子检测作为 FNA 细胞学检查辅助手段的作用。
Cytologic assessment of thyroid nodules – Updates in 2023 Bethesda reporting system, diagnostic challenges and pitfalls
This review summarizes changes and updates in the most recently published 2023 Bethesda System for Thyroid Cytopathology (TBSRTC). Further, the review focuses on challenges and pitfalls encountered in cytologic assessment of thyroid fine needle aspiration (FNA) specimens, with an emphasis on atypia of undetermined significance (TBSRTC category III) and the impact on risk of malignancy (ROM) among TBSRTC diagnostic categories following implementation of the terminology noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP). The role of molecular testing as an adjunct to FNA cytology will be discussed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
